Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 11/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL27576540 | 0.88 | AOC3 (0.45) | AOC3GAAKDM4EALDH1A1 | |
| SCHEMBL817422 | 0.83 | KDM4E (0.52) | AOC3GAAKDM4EALDH1A1HTR2A | |
| SCHEMBL1205734 | 0.83 | KDM4E (0.52) | AOC3GAAKDM4EALDH1A1HTR2A | |
| SCHEMBL1206432 | 0.83 | KDM4E (0.52) | AOC3GAAKDM4EALDH1A1HTR2A | |
| SCHEMBL4202700 | 0.79 | KDM4E (0.44) | AOC3KDM4EALDH1A1HTR2AHRH1 | |
| SCHEMBL10007040 | 0.78 | TRPA1 (0.43) | AOC3KDM4EALDH1A1HTR2AHRH1 | |
| SCHEMBL28794563 | 0.78 | KDM4E (0.47) | AOC3KDM4EALDH1A1HTR2AHRH1 | |
| SCHEMBL14018422 | 0.78 | KDM4E (0.47) | AOC3KDM4EALDH1A1HTR2AHRH1 | |
| SCHEMBL16333187 | 0.76 | GAA (0.46) | GAAKDM4EALDH1A1HTR2AHRH1 | |
| SCHEMBL11393827 | 0.76 | KDM4E (0.46) | AOC3KDM4EALDH1A1HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106654-A1 | Inhibitors of copper-containing amine oxidases | SMITH DAVID JOHN (FI) | 2004-06-03 | — | — | US | claimed |
| EP-1313718-A2 | INHIBITORS OF COPPER-CONTAINING AMINE OXIDASES | Biotie Therapies Corp. (FI) | 2003-05-28 | — | — | EP | claimed |
| US-20020173521-A1 | Inhibitors of copper-containing amine oxidases | BIOTIE THERAPIES CORP. | 2002-11-21 | — | — | US | claimed |
| WO-2002002090-A2 | INHIBITORS OF COPPER-CONTAINING AMINE OXIDASES | BIOTIE THERAPIES CORP. (FI) | 2002-01-10 | — | — | WO | claimed |
| US-20040106654-A1 | Inhibitors of copper-containing amine oxidases | SMITH DAVID JOHN (FI) | 2004-06-03 | — | — | US | disclosed |
| US-6624202-B2 | Antiinflammatory agents; antiarthritic agents; skin disorders | BIOTIE THERAPIES CORP. (FI) | 2003-09-23 | — | — | US | disclosed |
| EP-1313718-A2 | INHIBITORS OF COPPER-CONTAINING AMINE OXIDASES | Biotie Therapies Corp. (FI) | 2003-05-28 | — | — | EP | disclosed |
| US-20020173521-A1 | Inhibitors of copper-containing amine oxidases | BIOTIE THERAPIES CORP. | 2002-11-21 | — | — | US | disclosed |
| WO-2002002090-A2 | INHIBITORS OF COPPER-CONTAINING AMINE OXIDASES | BIOTIE THERAPIES CORP. (FI) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106654-A1 | Inhibitors of copper-containing amine oxidases | VCAM1, AOC3, AOC2 | AOC3 2/4885GAA 851/4885KDM4E 1735/4885 |
| US-20020173521-A1 | Inhibitors of copper-containing amine oxidases | VCAM1, AOC3, AOC2 | AOC3 2/4885GAA 851/4885KDM4E 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.